HEMS MEDICATION SECTION (INTERFACILITY TRANSFER)

CARDIZEM (DILTIAZEM)

Date: March 29, 2019 Section 9.46

Cardizem (Diltiazem)

Indications:

Interfacility transport of a patient where control of rapid ventricular response with A-fib/A-flutter or PSVT is initiated by the sending facility.

Contra-indications:

Allergy, hypotension, second and third degree heart block or V-tach.

Typical Sending Facility Initial Administration:

Initial dose 20 mg (0.25 mg/kg) slow IV push over 2 minutes. Second dose at 25 mg (0.35 mg/kg) slow IV push 15 minutes after first dose if indicated. DRIP: Continuous infusion at 5-15 mg/hr.

Procedure/Adverse Effects:

- 1. Establish a target heart rate range in discussion with the receiving facility, typically between 70 and 120 bpm.
- 2. Continue the diltiazem drip at the rate established by the sending facility.
- 3. If the heart rate is consistently (3-5 minutes) more than 10 bpm above the target rate increase the diltiazem drip in 5 mg increments every 15 minutes (up to 15 mg/hr total) as necessary to control heart rate.
- 4. If the heart rate is consistently (3-5 minutes) more than 10 bpm below the target rate stop the diltiazem drip.
- 5. Discontinue if patient develops hypersensitivity (rash) or hemodynamic instability (BP < 90 mm Hg).

**Not in Medication Box

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: